Psychiatr. praxi. 2012;13(2):69-74

Forced medication

MUDr.Alexander Nawka
Psychiatrická klinika 1. LF UK a VFN, Praha

Pharmacological treatment has in the algorithm of the management of an acutely agitated patient its indisputable place and should be initiated

only if previous de-escalation techniques and other non-pharmacological methods had fail. Ideal drug for such purpose should be

non-invasive; easy to apply; with rapid onset of action; effectively decreasing agitation without excessive sedation; well-tolerated and

should positively affect the underlying psychiatric condition. Despite the wide variety of currently available drugs nor one meets all the

criteria. The review article discusses the current treatment options for agitated patients with primary psychiatric causes of agitation.

Despite many existing „expert recommendations“ and the results of randomized controlled trials, a longlasting clinical experience

together with economical factors plays signifiant role in the use of forced medication.

Keywords: agitation, aggression, forced medication, pharmacotherapy, coercive measures

Published: April 23, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nawka A. Forced medication. Psychiatr. praxi. 2012;13(2):69-74.
Download citation

References

  1. Vevera J, Jirák R, Uhrová T, et al. Možnosti ovlivnění agitovaného a násilného chování v psychiatrické praxi. Psychiat praxi 2007; 2: 66-71.
  2. Owen C, Tarantello C, Jones M, et al. Violence and aggression in psychiatric units. Psychiatr Serv 1998; 49: 1452-1457. Go to original source... Go to PubMed...
  3. Vevera J, Hubbard A, Vesely A, Papezova H. Violent behaviour in schizophrenia. Retrospective study of four independent samples from Prague, 1949 to 2000. Br J Psychiatry 2005; 187: 426-440. Go to original source... Go to PubMed...
  4. Vevera J, Svarc J, Grohmannova K, et al. An increase in substance misuse rather than other mental disorders has led to increased forensic treatment rates in the Czech Republic. Eur Psychiatry 2009; 24: 380-387. Go to original source... Go to PubMed...
  5. Yang M, Wong SC, Coid J. The efficacy of violence prediction: A meta-analytic comparison of nine risk assessment tools. Psychological Bulletin 2010; 136: 740-767. Go to original source... Go to PubMed...
  6. Douglas KS, Guy LS, Hart S. Psychosis as a risk factor for violence to others: A meta-analysis. Psychological Bulletin 2009; 135: 679-706. Go to original source... Go to PubMed...
  7. Vevera J, Uhrová T, Jirák R, et al. Násilné chování a možnosti jeho ovlivnění (I) výskyt, rozdělení a klinické koreláty. Psychiatr. praxi 2002; 5: 40-43.
  8. Doubek P. Jak můžeme řešit agitovanost a neklid v ambulantní psychiatrické praxi? Psychiat praxi 2004; 5(3): 139-141.
  9. Vevera J, Jirák R, Uhrová T, et al. Možnosti farmakologického ovlivnění násilného chování u pacientů s demencí. Čes a slov Psychiat 2003; 3: 142-144.
  10. Hanušková V. Terapie akutního neklidu a agrese. Psychiatr. praxi 2008; 9: 172-117.
  11. Hýža M, Chvíla L. Terapie neklidu u duševních poruch způsobených psychoaktivními látkami. Psychiatr. praxi 2009; 10: 220-222.
  12. Chval J. Nejčastější příčiny neklidu na somatickém oddělení. Psychiatr. praxi 2008; 9: 164-165.
  13. Jirák R. Poruchy chování a nálady u demencí. Psychiatr. praxi 2011; 12: 56-60.
  14. Vevera J. Komunikace s agresivním pacientem. In: Ptáček R, Bartůněk P. Etika a komunikace v medicíně. Grada, Praha 2011: 381-387.
  15. Fulde G, Preisz P. Managing aggressive and violent patiens. Aust Prescr 2011; 34: 115-118. Go to original source...
  16. Raboch J, Anders M, Praško J, et al. Psychiatrie. Doporučené postupy psychiatrické péče II. Infopharm 2006: 204.
  17. Crowner ML. Understending and treating violent psychiatric patients. Washington DC, American Psychiatric Press, Inc., 2000.
  18. Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: A randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386-394. Go to original source... Go to PubMed...
  19. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther 2010; 32: 403-425. Go to original source... Go to PubMed...
  20. Atakan Z, Davies T. ABC of mental health. Mental health emergencies. BMJ 1997; 314: 1740-1742. Go to original source... Go to PubMed...
  21. Kerr IB, Taylor DM. Acute disturbed or violent behaviour principles of treatment. J Psychopharmacol 1997; 11: 271-277. Go to original source... Go to PubMed...
  22. Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982; 71: 248-252. Go to original source... Go to PubMed...
  23. Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract. 2006; 1: 30-40. Go to original source... Go to PubMed...
  24. McAllister - Williams RH, Ferrier IN. Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002; 180: 485-489. Go to original source... Go to PubMed...
  25. Fisman DN, Harris AD, Sorock GS, et al. Sharps-related injuries in health care workers: A casecrossover study. Am J Med 2003; 114: 688-694. Go to original source... Go to PubMed...
  26. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy conference of the European Society of Cardiology, Cardiovasc Res 2000; 47: 219-233. Go to original source... Go to PubMed...
  27. Hankin CS, Bronstone A, Koran LM. Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment. J Psychiatr Pract 2011; 17: 170-185. Go to original source... Go to PubMed...
  28. Battaglia J, Moss S, Rush J. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15: 335-340. Go to original source... Go to PubMed...
  29. Kališová L, Raboch J, a skupina EUNOMIA. Psychofarmaka podávaná při akutním neklidu - mezinárodní srovnání, projekt EUNOMIA. Psychiatrie 2008; 12(Suppl 1): 39.
  30. Raboch J, Kalisova L, Nawka A, et al. Use of coercive measures during involuntary hospitalization: Findings from ten European countries. Psychiatr Serv 2010;61:1012-1017. Go to original source... Go to PubMed...
  31. Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1998; 49: 184-188.
  32. Žukov I, Vevera J, Morcinek T. Farmakologické ovlivnění násilí. 42. Česko-slovenská psychofarmakologická konference. Sborník abstrakt, Galén 2000; 148.
  33. Kališová L, Raboch J, Číhal L, et al. Výsledky podrobného sledování použití omezovacích prostředků během hospitalizace - projekt EUNOMIA, výsledky v ČR. Čes. a slov. Psychiat 2008; 104: 52-58.
  34. Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65: 1207-1222. Go to original source... Go to PubMed...
  35. Sharif ZA. Pharmacokinetics, metabolism, and drugdrug interactions of atypical antipsychotics in special populations. Primary Care Companion. J Clin Psychiatry 2003; 5(Suppl 6): 22-25.
  36. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004; 24: 212-228. Go to original source... Go to PubMed...
  37. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Pharm Pharmacol 2006; 58: 871-885. Go to original source... Go to PubMed...
  38. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005; 11(Suppl 1): 5-108. Go to original source... Go to PubMed...
  39. National Institute for Health and Clinical Excellence. Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. London: Royal College of Nursing; 2006.
  40. Jaffe A, Levine J, Citrome L. "Stat" medication administration predicts hospital discharge. Psychiatr Q 2009; 80: 65-73. Go to original source... Go to PubMed...
  41. Mohr P, Pecenak J, Svestka J, et al. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett 2005; 26: 327-335. Go to PubMed...
  42. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. J Clin Psychopharmacol 2008; 28: 203-209. Go to original source... Go to PubMed...
  43. Satterthwaite TD, Wolf DH, Rosenheck RA, et al. A metaanalysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008; 69: 1869-1879. Go to original source... Go to PubMed...
  44. Miller DD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion. J Clin Psychiatry 2004; 6: 3-7.
  45. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61: 933-941. Go to original source... Go to PubMed...
  46. Lim HK, Kim JJ, Pae CU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study. Neuropsychobiology 2010; 62: 81-6. Go to original source... Go to PubMed...
  47. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-448. Go to original source... Go to PubMed...
  48. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipo bipolar mania. J Clin Psychopharmacol 2001; 21: 389-397. Go to original source... Go to PubMed...
  49. Citrome L. Aerosolised antipsychotic assuages agitation: Inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract 2011; 65: 330-340. Go to original source... Go to PubMed...
  50. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: Multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198: 51-58. Go to original source... Go to PubMed...
  51. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011 (v tisku). Go to original source...
  52. Nordstrom K. Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol 2009; 4: 539-545. Go to original source...
  53. Seifrtová D. Akutní neklid a agitovanost. Postgraduální medicína 2005: 7108-7111.
  54. Wyant M, Diamond B, O'Neal E, et al. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 1990; 26: 126-129. Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.